Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia-Reference-Cited by-同舟云学术

Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia

Published:2019-04-11 Issue: Volume: Page:
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kenzik Kelly M.¹²^ORCID,Bhatia Ravi²,Williams Grant R.¹²^ORCID,Bhatia Smita¹³

Affiliation:

1. Institute for Cancer Outcomes and Survivorship University of Alabama at Birmingham Birmingham Alabama

2. Division of Hematology and Oncology University of Alabama at Birmingham Birmingham Alabama

3. Division of Pediatric Oncology University of Alabama at Birmingham Birmingham Alabama

Funder

University of Alabama at Birmingham

American Cancer Society

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32137

Reference26 articles.

1. Surveillance Epidemiology and End Results Program National Cancer Institute.SEER Stat fact sheets: chronic myeloid leukemia (CML).http://seer.cancer.gov/statfacts/html/cmyl.html. Accessed July 1 2018.

2. Goldman’s Cecil Medicine 2011 Elsevier Saunders Philadelphia H Kantarjian S O’Brien L Goldman AI Schafer The chronic leukemias 1209 1218

3. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase;Jabbour EJ;J Med Econ,2017

4. Treatment patterns and healthcare costs among newly‐diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first‐line therapy in the United States;Latremouille‐Viau D;J Med Econ,2017

5. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia;Doshi JA;Am J Manag Care,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019;Cancer;2023-09-28

2. Management of chronic myeloid leukemia in 2023 – common ground and common sense;Blood Cancer Journal;2023-04-24

3. Therapeutic Role of Carotenoids in Blood Cancer: Mechanistic Insights and Therapeutic Potential;Nutrients;2022-05-06

4. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population‐based study;American Journal of Hematology;2021-05

5. Health Care Cost Associated With Contemporary Chronic Myelogenous Leukemia Therapy Compared With That of Other Hematologic Malignancies;JCO Oncology Practice;2021-03